Short answer
Arcus Biosciences, Inc. (RCUS) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $6M (down 87.5% year over year) with net income of −$135M.
Q3 2025 key financials · XBRL
- Revenue
- $6M
- −87.5% YoY · −25.0% QoQ
- Net income
- −$135M
- −46.7% YoY
- Operating margin
- -2366.7%
- EPS (diluted)
- −$1.30
- −27.5% YoY · −2700.0% QoQ
Source: XBRL data from the Arcus Biosciences, Inc. (RCUS) Q3 2025 10-Q on SEC EDGAR. USD.
Arcus Biosciences, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: Paused etrumadenant development in third-line metastatic colorectal cancer to focus resources on late-stage clinical portfolio and research programs
- Most updated risk: Cash $841M through pivotal readouts based on prioritization; risk of needing more capital could restrict R&D or cause dilution
- Regulatory risk: FDA may require additional studies to prove contribution of combination therapy components, delaying marketing approval
- Operational risk: Enrollment delays from competing trials and geopolitical instability could significantly increase costs or delay clinical trial completion
- Financial risk: Accumulated deficit $1.4B and net loss $247M for nine months 2025 highlight ongoing high cash burn and capital intensity
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcus Biosciences, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.